Healthcare News

Baba Raises $40 Million Series A to Scale AI-Supported Medicare Care Navigation

Baba announced on 20 October 2026 that it has closed a $40 million Series A led by FirstMark Capital, with participation from CVS Health Ventures and value-based care investor Valtruis and returning backers General Catalyst, Genius Ventures and Ground Up Ventures. The New York company gives each Medicare or Medicaid patient a dedicated human care team, care coordinators and licensed therapists, supported by AI agents that handle referrals, discharge tracking, in-home aide coordination, billing denials and applications for housing and transport support. Baba says it has supported more than 10,000 patients and families, with more than 100,000 families on its waiting list, and will use the funding to expand its clinical teams, advance its AI research and grow health-plan partnerships and value-based arrangements. Alongside the raise it released BabaBench, an arXiv preprint accepted to a NeurIPS workshop, which scores AI agents on completing long-horizon advocacy workflows without prohibited clinical actions or privacy violations. In June, the CMS Innovation Center selected Baba for the ACCESS Model across all four clinical tracks.

Baba Raises $40 Million Series A to Scale AI-Supported Medicare Care Navigation

Medicare navigation, the unglamorous work of referrals, discharge follow-up, billing disputes and benefit applications, has attracted a $40 million bet that AI can make it affordable at scale. Baba, a New York applied AI company, announced on 20 October 2026 that it has closed a $40 million Series A led by FirstMark Capital. CVS Health Ventures and the value-based care investor Valtruis joined the round, alongside returning investors General Catalyst, Genius Ventures and Ground Up Ventures. Baba's pitch is not an AI replacement for care coordinators. It is a human care team whose administrative load is carried by AI agents, offered to Medicare and Medicaid patients whose care is usually coordinated, unpaid, by family members.

What Was Announced

The company says the funding will expand its clinical care teams, advance its AI research and grow its partnerships with health plans, accelerating its value-based care arrangements. Baba reports that it has supported more than 10,000 patients and families across the United States, with more than 100,000 families on its waiting list, both figures are the company's own and are reported here as such. Its framing of the problem is demographic: nearly 70 million Americans have Medicare, the average Medicare patient sees over 40% more specialists a year than two decades ago, and more than 63 million Americans act as family caregivers. Founder and chief executive Connor Sweeney argues in the announcement that lowering the cost of coordinating care makes it viable to serve populations that have historically been too expensive to support. The round also follows a federal foothold: in June, the Centers for Medicare & Medicaid Services selected Baba for the ACCESS Model, the CMS Innovation Center's 10-year test of technology-supported chronic care, across all four of its clinical tracks, early cardio-kidney-metabolic, cardio-kidney-metabolic, musculoskeletal and behavioural health.

The Hybrid Model and the BabaBench Test

Every Baba patient is paired with a dedicated care team that includes care coordinators and licensed therapists or clinical social workers. The AI agents work underneath that team on logistics: synchronising specialist referrals, tracking hospital-to-home discharge transitions, coordinating in-home aide support, pursuing billing denials, and completing applications for housing assistance and medical transportation. Alongside the funding, Baba released BabaBench, a benchmark published as an arXiv preprint and accepted to an upcoming workshop at the NeurIPS conference. Where most AI evaluations test whether a model can answer a clinical question, BabaBench scores whether an agent can finish a long bureaucratic job, a multi-week insurance call sequence, a billing appeal, a prior authorisation dispute, from start to finish, without taking prohibited clinical actions and without a protected-health-information privacy violation. The distinction matters to buyers: a navigation agent that is fluent but abandons tasks halfway, or completes them by cutting privacy corners, is worse than useless in a regulated workflow.

What This Means for Care Coordination

For clinics, hospitals and health plans, the signal in this raise is about where AI investment is landing. The money is not going to another documentation tool. It is going to the coordination layer between organisations, the referrals that stall, the discharge instructions nobody follows up, the denials nobody appeals, which is where patient experience and leakage are actually decided. Providers evaluating similar services, or building their own navigation capacity, should note the structure Baba is selling: humans accountable for the relationship, agents accountable for the paperwork, and an outcomes-based payment route through models such as ACCESS rather than fee-for-service billing that pays nothing for coordination time. The discipline questions are the usual ones, applied to a new vendor class: Which tasks exactly do the agents perform, what is the escalation path to a licensed human, how is PHI handled and audited, and what completion rates, not satisfaction scores, does the vendor report? Practices strengthening their own front-door and follow-up workflows face the same design choices. Background reading is at https://medclinicx.com/blog/generative-ai-in-healthcare and https://medclinicx.com/solutions/ai-medical-receptionist.

Analysis: Navigation Is Becoming an AI Cost Problem

Analysis (MedClinicX): High-touch care navigation has always worked clinically and failed economically, a skilled coordinator can only carry so many complex patients, and traditional payment models rarely reimburse the hours involved. Baba's thesis is that AI agents change the denominator: if the referrals, calls and forms are largely automated, the same human team can carry a much larger panel, and value-based contracts can pay for the outcomes that follow. The waiting-list figure the company cites, if it holds up, suggests demand is not the constraint. Reimbursement and proof are. BabaBench is a smart credibility move in that context, publishing a completion-and-safety benchmark invites scrutiny competitors will have to match, but it is still the company's own test, released as a preprint. The evidence that will decide this category is duller: measured reductions in time-to-referral, denial recovery, readmissions and total cost for defined populations, published by the health plans paying for it. Until then, this raise is best read as informed investors pricing a real operational problem, not as proof the problem is solved.

Sources and References

  • Baba (via GlobeNewswire), Applied AI Company Baba Raises $40 Million Series A to Improve the Medicare Experience, 20 October 2026: https://www.globenewswire.com/news-release/2026/10/20/3384598/0/en/applied-ai-company-baba-raises-40-million-series-a-to-improve-the-medicare-experience.html
  • HIT Consultant, Baba Raises $40M to Expand Medicare Applied AI Platform, 20 October 2026: https://hitconsultant.net/2026/10/20/applied-ai-company-baba-raises-40m-series-a-firstmark-cvs-health-ventures-bababench-medicare/
  • The SaaS News, Baba Raises $40M Series A, 21 October 2026: https://www.thesaasnews.com/news/baba-raises-40m-series-a/

Reporting based on the sources above, accessed 21 October 2026. The Baba announcement and the HIT Consultant report were read directly in full. Patient, waiting-list and caregiver figures are company-reported and are attributed as such in the article. MedClinicX did not conduct original reporting or interviews for this article. Corrections: contact us via https://medclinicx.com/contact

Related Healthcare Technology Insights

Further reading to build your medical IT infrastructure strategy.

View all insights
Healthcare News

Oracle and AstraZeneca Partner to Use AI and Real-World Data to Match Patients to Clinical Trials

Oracle and AstraZeneca announced an agreement on 20 October 2026 to explore how artificial intelligence and real-world data can help clinicians identify patients eligible for clinical trials, speed up evidence generation, and carry research insights into everyday care, starting with areas such as oncology and cardiovascular disease.

October 20, 2026Read Article
Healthcare AI

Generative AI in Healthcare: 7 Practical Uses That Are Safe to Start With

Generative AI is safest in a clinic when it drafts and a person checks. Here are 7 practical uses to start with, what to avoid, the HIPAA rules, and a 4-week pilot plan.

October 19, 2026Read Article
Healthcare News

AI Tools Are Raising Healthcare Costs, Not Cutting Them, New PHTI Report Warns

Administrative AI built for documentation, coding, billing and prior authorization is increasing healthcare spending instead of reducing waste, according to a Peterson Health Technology Institute report released October 14, 2026.

October 15, 2026Read Article